biomed devic servic
expect sign improv still
earli maintain hold pt
bottom line maintain hold rate post result came slightli
ahead expect overal result encourag pocket
perform stabil us/emea continu apac strength remain
cautiou timelin need overcom oper issu prevent
share loss regain market share necessari compon acceler
top-lin growth unlock sharehold valu think
guidanc appropri conserv xfx sale growth commentari
impact oper ineffici remedi effort read
organ growth ep growth emphas time invest requir
turnaround stick hold
sum current valuat ep estim surpris
long-term investor start opportunist build posit next six
month particularli given manag provid enough forward inform
start piec togeth mosaic howev messag regard timelin
suppli new product turnaround sale momentum increasingli make
feel like late event reiter hold given expect share remain
range-bound upsid top-lin growth target look challeng
supply/manufactur issu weigh margin next month
top line post revenu cg/street estim
result show sign progress stabil key region
america emea apac continu strong momentum xfx
growth continu benefit weight legaci zimmer product
less affect suppli issu
manufactur qualiti call manag reiter confid
formal respons publicli releas fda warn letter
compani continu make progress remedi effort appear time
effort remain move target latest updat said
manag note suppli impact commerci execut point
continu think qualiti issu resolv remain cautiou regard
impact oper margin given increas invest manufactur
pipelin updat manag reiter expect pipelin product
play import part compani return sustain revenu earn
growth note zimmer highlight recent launch persona trabecular metal
tibia allow zimmer offer full cementless knee persona partial knee system
help fill knee portfolio look forward manag reiter
expect launch persona revis knee tka rosa robot system
view pipelin posit howev expect take
least product materi impact top-lin growth sentiment
manag reiter call
price close busi februari
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
zimmer report sale slightli estim
street revenu support strength asia pacif
region stabil busi america emea addit
qualiti remedi effort manufacturing/suppli issu continu
impact margin due higher product cost includ dual sourc inventori
outsid vendor invest end adjust gross margin came
y/i pro forma oper margin
y/i although worth note came slightli
expect zimmer report adjust ep compar estim
street
figur result vs estim consensu
come manag guid report sale growth rang
compar cg/consensu estim rang
includ expect neg bp fx impact impli improv
organ growth y/i pro forma ep expect guid
rang compar cg/consensu estim
adjust oper margin guid rang line
estim compani adjust tax rate expect
line estim free cash flow guid rang
consider lower estim
hold unchang target price februari
biomed devic servic
overal performanceactualcg estimatebeat/miss beat/miss consensusbeat/missnet good gross pro-forma oper net revenu productactualcg estimatebeat/miss beat/miss growthnet revenu geographyactualcg estimatebeat/miss beat/miss growthnet number us million zimmer biomet hold
chang estim
made follow chang estim
figur summari chang estim
broad large-cap med-tech group current trade mean price-to-earnings multipl
valu zimmer discount large-cap med-tech group given
uncertainti surround remedi suppli issu impact revenu
margin sum adjust pt base price-to-earnings multipl
appli pro-forma ep
hold unchang target price februari
biomed devic servic
except ep newold newold newold revenu gross operatin ebitda net zimmer biomet hold
figur matrix discount rate impli share price target
zimmer biomet
zimmer world-wide leader design develop manufactur market
reconstruct spinal implant trauma relat orthoped surgic product
hold unchang target price februari
biomed devic servic
comp pe multipl price metric use price-to-earnings valuat analysisbroad large-cap medic devic price-to-earnings multipl adjust pro-forma figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
hold unchang target price februari
biomed devic servic
zimmer biomet incom statementcanaccord genuiti kyle except per share good devic gener asset op incom chg chg amort stk incom minor incom ep ep one-tim ep chg share gener oper rate adjust growth growth ep ex compani document canaccord genuiti estim figur pro forma revenu build
hold unchang target price februari
biomed devic servic
zimmer biomet revenu buildcanaccord genuiti kyle euro yen fx impact impact fx growth growth zimmer biomet hold
